Antitumor effect of somatostatin analogs in neuroendocrine tumors

Journal of Clinical Oncology

Volumn 28, Issue 3, 2010, Pages

  Chua, Yu Jo ^a   Michael, Michael ^b   Zalcberg, John R ^b   Hicks, Rod J ^b   Goldstein, David ^c   Liauw, Winston ^d   Price, Timothy ^e  

^a CANBERRA HOSPITAL   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c PRINCE OF WALES HOSPITAL   (Australia)

^d ST GEORGE HOSPITAL   (Australia)

^e QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLECYSTOKININ; PLACEBO; SOMATOSTATIN DERIVATIVE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; OCTREOTIDE; SOMATOSTATIN;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CARCINOID SYNDROME; HISTOLOGY; INTESTINE; LETTER; LIVER; METASTASIS; NEUROENDOCRINE TUMOR; OUTCOME ASSESSMENT; PRIORITY JOURNAL; WORLD HEALTH ORGANIZATION; FEMALE; HUMAN; MALE; NOTE;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; NEUROENDOCRINE TUMORS; OCTREOTIDE; SOMATOSTATIN;

EID: 75749136964     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.26.0612     Document Type: Letter

References (3)

1. Rinke A, Muller HH, Schade-Brittinger C, et al: Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group. J Clin Oncol 27:4656-4663, 2009
2. Oberg K: Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors. Expert Rev Anticancer Ther 9:557-566, 2009
3. National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology 2009-Neuroendocrine Tumors, Version 2